Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Researchers have identified a potential therapeutic target for inflammatory bowel diseases. The findings are of particular importance to the 40% of patients who don’t respond to anti-TNF therapy, the current treatment option available. Professor Simon Travis co-led this study.